Indegene Ltd
Incorporated in 1998, Indegene Ltd provides
solutions consisting of analytics, technology
and commercial, medical, regulatory and
safety services to life science and health
care organizations[1]
- Market Cap ₹ 14,806 Cr.
- Current Price ₹ 619
- High / Low ₹ 737 / 469
- Stock P/E 84.0
- Book Value ₹ 74.1
- Dividend Yield 0.00 %
- ROCE 18.4 %
- ROE 14.2 %
- Face Value ₹ 2.00
Pros
- Company has reduced debt.
- Company is almost debt free.
- Company has a good return on equity (ROE) track record: 3 Years ROE 18.9%
Cons
- Stock is trading at 8.35 times its book value
- Though the company is reporting repeated profits, it is not paying out dividend
- Earnings include an other income of Rs.81.5 Cr.
* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.
Peer comparison
Sector: Healthcare Industry: Miscellaneous
Part of Nifty 500 Nifty MidSmallcap 400 Nifty 500 Multicap 50:25:25 BSE Allcap BSE IPO
Quarterly Results
Standalone Figures in Rs. Crores / View Consolidated
Profit & Loss
Standalone Figures in Rs. Crores / View Consolidated
Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | TTM | |
---|---|---|---|---|---|---|---|
282 | 334 | 511 | 837 | 1,006 | 1,046 | 1,100 | |
230 | 249 | 361 | 668 | 828 | 878 | 915 | |
Operating Profit | 53 | 86 | 150 | 169 | 178 | 168 | 184 |
OPM % | 19% | 26% | 29% | 20% | 18% | 16% | 17% |
12 | -24 | 30 | 28 | 37 | 50 | 82 | |
Interest | 1 | 3 | 4 | 3 | 6 | 7 | 6 |
Depreciation | 4 | 13 | 18 | 24 | 32 | 31 | 27 |
Profit before tax | 59 | 46 | 159 | 170 | 177 | 181 | 233 |
Tax % | 14% | 30% | 17% | 22% | 26% | 24% | |
51 | 32 | 132 | 133 | 130 | 138 | 176 | |
EPS in Rs | 324.22 | 202.30 | 843.58 | 755.26 | 5.87 | 6.20 | 7.52 |
Dividend Payout % | 0% | 0% | 0% | 0% | 0% | 0% |
Compounded Sales Growth | |
---|---|
10 Years: | % |
5 Years: | 30% |
3 Years: | 27% |
TTM: | 7% |
Compounded Profit Growth | |
---|---|
10 Years: | % |
5 Years: | 20% |
3 Years: | -1% |
TTM: | 51% |
Stock Price CAGR | |
---|---|
10 Years: | % |
5 Years: | % |
3 Years: | % |
1 Year: | % |
Return on Equity | |
---|---|
10 Years: | % |
5 Years: | 26% |
3 Years: | 19% |
Last Year: | 14% |
Balance Sheet
Standalone Figures in Rs. Crores / View Consolidated
Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Sep 2024 | |
---|---|---|---|---|---|---|---|
Equity Capital | 0.31 | 0.30 | 0.30 | 0.40 | 44 | 44 | 48 |
Reserves | 158 | -3 | 254 | 650 | 751 | 909 | 1,726 |
106 | 362 | 23 | 44 | 51 | 38 | 32 | |
57 | 72 | 96 | 156 | 191 | 228 | 240 | |
Total Liabilities | 322 | 431 | 373 | 850 | 1,038 | 1,220 | 2,046 |
8 | 31 | 41 | 72 | 78 | 56 | 47 | |
CWIP | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Investments | 134 | 251 | 83 | 203 | 400 | 624 | 784 |
180 | 148 | 249 | 575 | 559 | 540 | 1,215 | |
Total Assets | 322 | 431 | 373 | 850 | 1,038 | 1,220 | 2,046 |
Cash Flows
Standalone Figures in Rs. Crores / View Consolidated
Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | |
---|---|---|---|---|---|---|
62 | 90 | 53 | 38 | 82 | 176 | |
-70 | -51 | -34 | -267 | -51 | -189 | |
15 | -18 | -37 | 245 | -17 | -16 | |
Net Cash Flow | 8 | 20 | -18 | 16 | 14 | -29 |
Ratios
Standalone Figures in Rs. Crores / View Consolidated
Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | |
---|---|---|---|---|---|---|
Debtor Days | 65 | 65 | 125 | 152 | 145 | 132 |
Inventory Days | ||||||
Days Payable | ||||||
Cash Conversion Cycle | 65 | 65 | 125 | 152 | 145 | 132 |
Working Capital Days | 51 | 21 | 84 | 107 | 118 | 109 |
ROCE % | 28% | 49% | 36% | 24% | 18% |
Documents
Announcements
-
Integrated Filing (Financial)
9h - Board approved unaudited financial results for Q3 2024.
-
Announcement under Regulation 30 (LODR)-Earnings Call Transcript
6 Feb - [LODR], Regulation, 2015, please find enclosed the transcript of the conference call for the quarter ended December 31, 2024, conducted after the meeting of the …
-
Announcement under Regulation 30 (LODR)-Press Release / Media Release
6 Feb - Indegene launches new entity in Spain for expansion.
-
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Outcome
31 Jan - Audio recording of Q3FY25 earnings call available.
-
Intimation Of Opening Of Trading Window .
31 Jan - Opening of trading window for designated persons.
Concalls
-
Feb 2025Transcript PPT
-
Nov 2024Transcript PPT
-
Aug 2024Transcript PPT
-
Aug 2024TranscriptNotesPPT
-
Jun 2024TranscriptPPTREC
Business Overview:[1]
IL is a digital-first healthcare and technology company. It helps bio pharmaceutical, emerging biotech and medical device companies to develop products and get them to market. Company brings together healthcare domain expertise, technology and an agile operating model to provide diverse solutions for patients and physicians.